



ProstaLund´s CoreTherm® has passed the efficacy and safety evaluation by "Nye Metoder" in Norway

Bestillerforum in "Nye Metoder" in Norway has decided to let the four regional "helseforetaken" take the decision whether CoreTherm® (TUMT) should be implemented as a method for the treatment of benign prostate enlargement in public healthcare.

«Nye metoder» is a system in Norway based on close cooperation between «spesialisthelsetjenesten ved de regionale helseforetakene, helseforetakene (sykehusene), Statens legemiddelverk, Folkehelseinstituttet, Statens Strålevern og Helsedirektoratet.» A key task of «Nye Metoder» is to evaluate the efficacy, safety and cost-effectiveness of new treatments while comparing with existing ones. The evaluations form an important part of the knowledge base for decisions on the possible introduction or phasing out of methods in public healthcare in Norway.

Bestillerforum's meeting minutes from Monday: "Transuretral mikrobølgebehandling (TUMT) til behandling av benign prostatahyperplasi kompletteres med kostnadsdata fra Folkehelseinstituttets møtenotat til Bestillerforum og sendes til beslutning i de regionale helseforetakene."

It is worth noting from the protocol that the method *photoselective vaporization* for the treatment of BPH is interrupted as efficacy and safety data are insufficient to be able to prioritize between different techniques.

CEO Johan Wennerholm comments:

"It is gratifying to hear that "Nye Metoder", based on existing data on the efficiency and safety of the method, gives the Norwegian regions the green light to decide whether to offer CoreTherm. Today, CoreTherm is only performed at a private clinic in Oslo. Now we are one step closer to a broader use of CoreTherm® in public healthcare in Norway."

For further information, please contact:

Johan Wennerholm, Acting CEO
Tel. +46 (0) 730 429997
Email: johan.wennerholm@prostalund.com



PRESS RELEASE
24 June 2021 10:30:00 CEST

About ProstaLund

ProstaLund AB is a Swedish medical technology company and a leading developer and manufacturer of innovative urological devices and treatments. The company's lead product, CoreTherm, is a patented Thermotherapy treatment method for Benign Prostatic Hyperplasia (BPH) which can be tailored to suit the needs of each individual patient. CoreTherm is used today in hospitals and clinics in Sweden and worldwide. ProstaLund is listed on the Nasdaq First North Growth Market.

Certified Adviser:

Västra Hamnen Corporate Finance AB

Phone: +46 40 200 250

E-mail: ca@vhcorp.se

Attachments

ProstaLund's CoreTherm® has passed the efficacy and safety evaluation by "Nye Metoder" in Norway